Carcinoma, Intraductal, Noninfiltrating
"Carcinoma, Intraductal, Noninfiltrating" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A noninvasive (noninfiltrating) carcinoma of the breast characterized by a proliferation of malignant epithelial cells confined to the mammary ducts or lobules, without light-microscopy evidence of invasion through the basement membrane into the surrounding stroma.
| Descriptor ID |
D002285
|
| MeSH Number(s) |
C04.557.470.200.025.275 C04.557.470.200.240.187.250 C04.557.470.615.275
|
| Concept/Terms |
Carcinoma, Intraductal, Noninfiltrating- Carcinoma, Intraductal, Noninfiltrating
- Carcinoma, Intraductal
- Carcinomas, Intraductal
- Intraductal Carcinoma
- Intraductal Carcinomas
- DCIS
- Ductal Carcinoma In Situ
- Intraductal Carcinoma, Noninfiltrating
- Carcinoma, Noninfiltrating Intraductal
- Carcinomas, Noninfiltrating Intraductal
- Intraductal Carcinomas, Noninfiltrating
- Noninfiltrating Intraductal Carcinoma
- Noninfiltrating Intraductal Carcinomas
Atypical Ductal Hyperplasia- Atypical Ductal Hyperplasia
- Atypical Ductal Hyperplasias
- Ductal Hyperplasia, Atypical
- Ductal Hyperplasias, Atypical
- Hyperplasia, Atypical Ductal
- Hyperplasias, Atypical Ductal
|
Below are MeSH descriptors whose meaning is more general than "Carcinoma, Intraductal, Noninfiltrating".
- Diseases [C]
- Neoplasms [C04]
- Neoplasms by Histologic Type [C04.557]
- Neoplasms, Glandular and Epithelial [C04.557.470]
- Carcinoma [C04.557.470.200]
- Adenocarcinoma [C04.557.470.200.025]
- Carcinoma, Intraductal, Noninfiltrating [C04.557.470.200.025.275]
- Carcinoma in Situ [C04.557.470.200.240]
- Breast Carcinoma In Situ [C04.557.470.200.240.187]
- Carcinoma, Intraductal, Noninfiltrating [C04.557.470.200.240.187.250]
- Neoplasms, Ductal, Lobular, and Medullary [C04.557.470.615]
- Carcinoma, Intraductal, Noninfiltrating [C04.557.470.615.275]
Below are MeSH descriptors whose meaning is more specific than "Carcinoma, Intraductal, Noninfiltrating".
This graph shows the total number of publications written about "Carcinoma, Intraductal, Noninfiltrating" by people in this website by year, and whether "Carcinoma, Intraductal, Noninfiltrating" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 1 | 1 | 2 |
| 2001 | 1 | 0 | 1 |
| 2002 | 1 | 1 | 2 |
| 2004 | 1 | 0 | 1 |
| 2006 | 1 | 0 | 1 |
| 2007 | 2 | 0 | 2 |
| 2008 | 1 | 0 | 1 |
| 2009 | 0 | 1 | 1 |
| 2011 | 2 | 2 | 4 |
| 2012 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 2 | 0 | 2 |
| 2015 | 5 | 0 | 5 |
| 2017 | 0 | 2 | 2 |
| 2018 | 3 | 1 | 4 |
| 2020 | 4 | 0 | 4 |
| 2021 | 2 | 0 | 2 |
| 2022 | 3 | 0 | 3 |
| 2023 | 1 | 0 | 1 |
| 2024 | 2 | 0 | 2 |
| 2025 | 1 | 0 | 1 |
| 2026 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Carcinoma, Intraductal, Noninfiltrating" by people in Profiles.
-
Oncocytic Intraductal Carcinoma of the Parotid Gland with STRN::ALK Fusion. Head Neck Pathol. 2026 Jun 30; 20(1).
-
Impact of systematic cavity shave margins in breast-conserving surgery at a large community hospital with a low baseline re-excision rate. Breast J. 2020 10; 26(10):1960-1965.
-
onlineDeCISion.org: a web-based decision aid for DCIS treatment. Breast Cancer Res Treat. 2015 Nov; 154(1):181-90.
-
A Molecular Portrait of High-Grade Ductal Carcinoma In Situ. Cancer Res. 2015 Sep 15; 75(18):3980-90.
-
The Status of STAT3 and STAT5 in Human Breast Atypical Ductal Hyperplasia. PLoS One. 2015; 10(7):e0132214.
-
Histopathologic correlation of residual mammographic microcalcifications after neoadjuvant chemotherapy for locally advanced breast cancer. Ann Surg Oncol. 2015 Apr; 22(4):1111-7.
-
Adverse surgical outcomes in screen-detected ductal carcinoma in situ of the breast. Eur J Cancer. 2014 Jul; 50(11):1880-90.
-
Two histopathologically different diseases: hormone receptor-positive and hormone receptor-negative tumors in HER2-positive breast cancer. Breast Cancer Res Treat. 2014 Jun; 145(3):615-23.
-
Which threshold for ER positivity? a retrospective study based on 9639 patients. Ann Oncol. 2014 May; 25(5):1004-11.
-
Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence. Breast Cancer Res. 2014; 16(6):3417.